Posterior Circulation Stroke

This course provides a review of the clinical characteristics of posterior circulation stroke symptoms and an evidence-based review of the implication of clinical trial data on treatment options.

Target Audience

Adult and Pediatric Neurologists, Neurosurgeons, Stroke Neurologists, Neuroradiologists, Diagnostic Radiologists, Critical Care Physicians, Neurointensivists, Emergency Medicine Physicians, Internal Medicine Physicians, Interventional Neuroradiologists, Family Physicians, General Internists, Rehabilitation and Pain Management Specialists, Clinical Pharmacists, as well as other specialists interested in the field of neuroscience.

Learning Objectives

  • Identify patients with posterior circulation stroke.
  • Recognize the limitations associated with clinical scale assessments that determine eligibility for acute reperfusion treatment.
  • Determine when to triage posterior circulation stroke patients to ICU, neuro-stepdown or floor.
  • Select patients for early surgical decompression or medical cytotoxic edema treatment.
     
Additional information
Bibliography: 
  • Adams, D. S. (1996). Stroke rehabilitation: indications, outcomes, recent developments. The Journal of the Louisiana State Medical Society: official organ of the Louisiana State Medical Society, 148(11), 498-502.
  • Arboix, A., Arbe, G., García-Eroles, L., Oliveres, M., Parra, O., & Massons, J. (2011). Infarctions in the vascular territory of the posterior cerebral artery: clinical features in 232 patients. BMC research notes, 4(1), 329.
  • Kwon, J. Y., Kwon, S. U., Kang, D. W., Suh, D. C., & Kim, J. S. (2012). Isolated lateral thalamic infarction: the role of posterior cerebral artery disease. European journal of neurology, 19(2), 265-270.
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 General certificate of attendance
  • 0.50 Florida Board of Pharmacy
Course opens: 
02/01/2019
Course expires: 
01/31/2022

Brett Kissela, M.D., M.S.
Professor and Chair
Department of Neurology and Rehabilitation Medicine
Senior Associate Dean of Clinical Research
University of Cincinnati College of Medicine
Chief of Research Services, UC Health
Cincinnati, Ohio

Brett Kissela, M.D., faculty for this educational activity, indicated that he is a consultant with Allegan and Ipsen and on the adjudication clinical trail committee for AbbVie and Janssen and has indicated that the presentation or discussion will not include off-label or unapproved product usage.

PLANNING COMMITTEE

Kevin Abrams, M.D., indicated that he is a consultant and shareholder with Keystone Heart.

Guilherme Dabus, M.D., indicated that he is a consultant for Microvention/Terumo, Medtronic, Penumbra and Cerenovus, and on the speakers' bureau for Microvention/Terumo, Medtronic and Penumbra. He is a proctor for Medtronic. Dr. Dabus is also a shareholder with Surpass Medical/Stryker, Medina/Medtronic, InNeuro Co and Three Rivers Medical.

Daniel D’Amour, M.D., Felipe De Los Rios, M.D., Karel Fuentes, M.D., Sergio Gonzalez-Arias, M.D., Ph.D., Kunal Patel, M.S., Amy K. Starosciak, Ph.D., and Jayme Strauss, R.N., MSN, have no relevant financial relationship with ineligible companies* to disclose.

Bruno V. Gallo, M.D., indicated that he is on speakers' bureau for Teva Pharmaceuticals and Sunovion Pharmaceuticals. He receives grant support for Medtronic International, Pfizer Pharmaceuticals, Glaxo-SmithKline and St. Jude Medical, Inc. Dr. Gallo serves as a consultant for Cyberonics, Teva Pharmaceuticals, St. Jude Medical, ONS Inc. and Sugimon LLC.

Italo Linfante, M.D., indicated that he is a consultant for Medtronic, Stryker and Penumbra. He is a stockholder with InNeuro Co.

Alberto Pinzon-Ardila, M.D., indicated that he is on the speakers' bureau for Sunovion Pharmaceuticals and UCB.

All of the relevant financial relationships listed for these individuals have been mitigated.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*. 

*Ineligible companies -- Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
              
Baptist Health South Florida designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 General certificate of attendance
  • 0.50 Florida Board of Pharmacy
Please login or register to take this course.

Required Hardware/software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome
Microsoft Edge
Microsoft Edge
Safari
Safari
Moxilla Firefox
Mozilla Firefox
Internet Explorer

Attention: Internet Explorer Users
This site offers limited support for Internet Explorer 11 (IE11). When using IE11, you will be prompted to download course videos instead of viewing them in the browser. After the course video downloads, the recordings will play.

Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.